+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating new treatment options for people with locally advanced, unresected non-small cell lung cancer NSCLC that has a KRAS G12C gene mutation. This trial aims to learn if combining calderasib MK-1084 with durvalumab, an immunotherapy, after chemotherapy and radiation can help patients live longer without their cancer growing or spreading. Participants will be randomly assigned to receive either calderasib along with durvalumab or a placebo with durvalumab. Calderasib is taken as an oral tablet, while durvalumab is given by intravenous infusion. The study is blinded so neither participants nor researchers know who receives the active drug or placebo during treatment. During the study, participants will be monitored regularly to assess cancer progression, survival, quality of life, and side effects. This includes tumor testing, blood work, and questionnaires over up to approximately 6 years for progression-free survival and up to 9 years for overall survival and other health measures. The study is sponsored by Merck Sharp & Dohme LLC and follows participants from screening through long-term follow-up.

Age: 18Years +All GendersPhase 3
107 locations
P

Actively Recruiting

Researchers are evaluating the combination of calderasib and pembrolizumab as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer NSCLC that has a specific KRAS G12C mutation and a PD-L1 tumor proportion score of 50% or higher. The study aims to determine if this combination improves progression-free survival compared to pembrolizumab with placebo. This is a phase 3 randomized, double-blind trial sponsored by Merck Sharp & Dohme LLC. Participants will receive pembrolizumab 200 mg through intravenous infusion on the first day of each 21-day cycle, continuing for up to 35 cycles. In addition, they will take either calderasib or placebo tablets daily until they meet discontinuation criteria. The study includes two groups one receiving calderasib plus pembrolizumab and the other receiving placebo plus pembrolizumab. No new participants will be offered a second course of pembrolizumab. Throughout the study, participants will undergo various assessments including tumor evaluations by central review to measure progression-free survival, overall survival, and response rates. Quality of life and physical functioning will be monitored using standardized questionnaires up to 24 months. Safety will be tracked by recording adverse events and treatment discontinuations for up to approximately 80 months. The total study duration extends up to 7 years, with ongoing monitoring throughout.

Age: 18Years +All GendersPhase 3
246 locations
S

Actively Recruiting

Researchers are studying the safety and effectiveness of a medicine called MK-1084 in treating Non-Small Cell Lung Cancer NSCLC with a specific gene change known as KRAS G12C. This study aims to find out how many participants experience tumor shrinkage or disappearance while receiving this treatment. The study is a Phase 2 trial focused on advanced or metastatic nonsquamous NSCLC with this genetic mutation. Participants receive one of three treatments Pembrolizumab plus MK-1084 Pembrolizumab, MK-1084, and Cetuximab or Pembrolizumab, MK-1084, and sacituzumab tirumotecan sac-TMT. Pembrolizumab is given intravenously every 6 weeks, MK-1084 is taken orally, and Cetuximab or sac-TMT are given intravenously every 2 weeks depending on the assigned group. Rescue medications are also provided to reduce side effects like infusion reactions and mouth sores. During the study, participants undergo evaluations for side effects and tumor response at various time points, including up to approximately 84 months for long-term safety and effectiveness monitoring. Researchers assess dose-limiting toxicities, adverse events, and how many participants stop treatment because of side effects. Tumor response is measured using established criteria, and blood samples are collected to study MK-1084 levels. The total study duration extends until 2032, allowing for extended follow-up.

Age: 18Years +All GendersPhase 2
39 locations
L

Actively Recruiting

Researchers are studying the long-term safety and effectiveness of pembrolizumab MK-3475 in participants with advanced tumors or blood cancers who were part of previous pembrolizumab-based studies. This extension study includes participants currently receiving treatment or in follow-up from parent trials. It consists of three phases the First Course Phase, Survival Follow-up Phase, and Second Course Phase, depending on the participants status at the end of their previous study. Participants may receive pembrolizumab alone or combined with standard of care treatments, lenvatinib, or other study drugs like olaparib and MK-4280, delivered mainly by intravenous infusion or oral capsules. Dosing schedules vary, including pembrolizumab administered every 3 or 6 weeks for up to 35 or 17 doses depending on the phase. Some participants may take lenvatinib orally daily, timed with pembrolizumab infusions, while others may receive investigational combination therapies or standard care treatments according to their parent studys protocol. During the study, participants will have regular infusions or oral dosing and be monitored over several years for overall survival and other outcomes like progression-free survival and adverse events. Researchers will assess safety and efficacy for up to approximately 10 years, with detailed tracking of side effects and treatment discontinuations. Study visits and assessments will be conducted to evaluate organ function, disease status, and any treatment-related effects throughout the study duration.

Age: 18Years +All GendersPhase 3
782 locations
S

Actively Recruiting

Researchers are evaluating the use of adjuvant calderasib combined with subcutaneous pembrolizumab and berahyaluronidase alfa MK-3475A compared to adjuvant placebo plus MK-3475A in participants with completely resected stage IIA-IIIB N2, KRAS G12C-mutant non-small cell lung cancer. This phase 3, randomized, double-blind study focuses on participants who have previously received either neoadjuvant pembrolizumab plus chemotherapy or adjuvant chemotherapy. The main goal is to compare disease-free survival between the treatment groups. Participants are assigned to one of two groups one group receives daily calderasib and MK-3475A every six weeks for up to nine doses, while the other group receives a daily placebo plus MK-3475A on the same schedule. The study treatments are administered as oral tablets for calderasib or placebo, and subcutaneous injections for MK-3475A. Treatment continues for up to nine doses or until disease progression or other criteria are met. During the study, participants will undergo regular assessments including imaging scans such as contrast-enhanced chest or abdomen CT or MRI to confirm no evidence of disease before starting treatment. Researchers will monitor disease-free survival up to approximately 11 years, along with overall survival, lung cancer specific survival, distant metastasis-free survival, quality of life measures, and safety outcomes. Adverse events and treatment discontinuations will be tracked for up to 13.5 years, ensuring long-term safety and efficacy monitoring.

Age: 18Years +All GendersPhase 3
120 locations